The role of advanced lipid testing in the prediction of cardiovascular disease

Current Atherosclerosis Reports

Volumn 16, Issue 3, 2014, Pages

  Chandra, Alvin ^a   Rohatgi, Anand ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Diet; Exercise; Lipoprotein; Particles

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN;

ADVANCED LIPID TESTING; ARTICLE; BODY MASS; CALORIC RESTRICTION; CARBOHYDRATE DIET; CHEMICAL ANALYSIS; DIET; DIET RESTRICTION; ENDURANCE TRAINING; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PREDICTION; VERTICAL AUTO PROFILE TEST; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; EXERCISE; FEEDING BEHAVIOR; IMMUNOASSAY; LIPID METABOLISM; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION;

APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; EXERCISE; FOOD HABITS; HUMANS; HYPOLIPIDEMIC AGENTS; IMMUNOASSAY; LIPID METABOLISM; LIPOPROTEINS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 84892451535     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0394-9     Document Type: Article

References (34)

1. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
2. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316-22.
3. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50-103.
4. •• Mackey RH, Greenland P, Goff Jr DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012;60:508-16. MESA is a large multiethnic observational study of healthy participants. This analysis found that total HDL-P concentration is inversely associated with prevalent carotid atherosclerosis and incident coronary events, even when adjusted for risk factors and HDL-C concentration.
5. Albers JJ, Marcovina SM, Kennedy H. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem. 1992;38:658-62.
6. • Grundy SM, Vega GL, Tomassini JE, Tershakovec AM. Comparisons of apolipoprotein b levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI trial). Am J Cardiol. 2011;108:40-6. This study compares various advanced lipid measurement methods for measuring apo B levels.
7. Chung M, Lichtenstein AH, Ip S, Lau J, Balk EM. Comparability of methods for LDL subfraction determination: a systematic review. Atherosclerosis. 2009;205:342-8.
8. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2595-600. (Pubitemid 38766337)
9. Couillard C, Despres JP, Lamarche B, Bergeron J, Gagnon J, Leon AS, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: Evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 2001;21:1226-32. (Pubitemid 34215155)
10. Magkos F, Mohammed BS, Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int J Obes. 2008;32:1655-64.
11. Mantyselka P, Kautiainen H, Saltevo J, Wurtz P, Soininen P, Kangas AJ, et al. Weight change and lipoprotein particle concentration and particle size: a cohort study with 6.5-year follow-up. Atherosclerosis. 2012;223:239-43.
12. Varady KA, Bhutani S, Klempel MC, Kroeger CM. Comparison of effects of diet versus exercise weight loss regimens on LDL and HDL particle size in obese adults. Lipids Health Dis. 2011;10:119.
13. Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Varady KA. Alternate day fasting and endurance exercise combine to reduce body weight and favorably alter plasma lipids in obese humans. Obesity (Silver Spring). 2013;21:1370-9.
14. Huffman KM, Hawk VH, Henes ST, Ocampo CI, Orenduff MC, Slentz CA, et al. Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I. Am Heart J. 2012;164:117-24.
15. Guay V, Lamarche B, Charest A, Tremblay AJ, Couture P. Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. Metabolism. 2012;61:76-83.
16. Faghihnia N, Tsimikas S, Miller ER, Witztum JL, Krauss RM. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res. 2010;51:3324-30.
17. LeCheminant JD, Smith BK, Westman EC, Vernon MC, Donnelly JE. Comparison of a reduced carbohydrate and reduced fat diet for LDL, HDL, and VLDL subclasses during 9-months of weight maintenance subsequent to weight loss. Lipids Health Dis. 2010;9:54.
18. Blesso CN, Andersen CJ, Barona J, Volek JS, Fernandez ML. Whole egg consumption improves lipoprotein profiles and insulin sensitivity to a greater extent than yolk-free egg substitute in individuals with metabolic syndrome. Metabolism. 2013;62:400-10.
19. Bogl LH, Maranghi M, Rissanen A, Kaprio J, Taskinen MR, Pietilainen KH. Dietary omega-3 polyunsaturated fatty acid intake is related to a protective high-density lipoprotein subspecies profile independent of genetic effects: a monozygotic twin pair study. Atherosclerosis. 2011;219:880-6.
20. Rosenson RS, Underberg JA. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther. 2013;27:465-79.
21. Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
22. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: Reconciling the aim-high (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: Impact on global health outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol. 2012;59:2058-64.
23. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of er niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-91.
24. Morgan JM, Carey CM, Lincoff A, Capuzzi DM. The effects of niacin on lipoprotein subclass distribution. Prev Cardiol. 2004;7:182-7. quiz 188.
25. • Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich Jr PO, et al. Relationship of apolipoproteins A-1 and b, and lipoprotein (a) to cardiovascular outcomes. The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62:1575-9. This study analyzes the lipoprotein changes with niaspan in the AIM-HIGH trial and associations between baseline and on-treatment lipoprotein levels and incident cardiovascular events.
26. Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs. 2012;72:491-507.
27. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation. 2010;121:52-62.
28. Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012;163:515-521.e3.
29. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-99.
30. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-62. (Pubitemid 36173203)
31. •• Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, et al. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013;98:3989-98. The Diabetes Prevention Program is the one of the trials in patients with diabetes to show improvement in hard cardiovascular outcomes. This analysis looks at the association between lifestyle and metformin and lipoprotein composition in the trial.
32. Howard WJ, Russell M, Fleg JL, Mete M, Ali T, Devereux RB, et al. Prevention of atherosclerosis with LDL-C lowering - lipoprotein changes and interactions: The SANDS study. J Clin Lipidol. 2009;3:322-31.
33. Moin DS, Rohatgi A. Clinical applications of advanced lipoprotein testing in diabetes mellitus. Clin Lipidol. 2011;6:371-87.
34. • Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013;128:1189-97. This study shows that in patients receiving high-dose statin therapy, HDL-P concentration is inversely associated with cardiovascular events but HDL-C concentration is not.